SecBot SecBot
8-K ·Filed Nov 12, 2026

GRCE

Grace Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 17h ago SEC0001140361-26-043308
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor progress on NDA resubmission for GTx-104, as the dual-source manufacturing strategy and FDA reinspection timing are the key catalysts. The company's cash runway through end of 2028 provides a long operational runway, but no revenue is expected until potential FDA approval.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+1
Entry
$1.81
T+0 close · Nov 12, 2026 · via day close
Latest settled
0.00%
T+1 · $1.81
Vs SPY
+0.36%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $1.81entry
  2. T+1 · 4d ago 0.00%α +0.36% · $1.81
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Grace Therapeutics reported a Q2 2027 net loss of $2.1 million ($0.11 per share), wider than the $0.9 million loss in the prior-year quarter, driven by the expiration of warrant-related gains and higher R&D spending on its dual-source manufacturing strategy for GTx-104. Cash runway extends through end of calendar 2028, and the company continues to address FDA CMC items from the April 2026 Complete Response Letter with no new clinical data required.

Key Financial Metrics

EPS
−$0.11

Key Facts

  • Net loss of $2.1 million ($0.11 per share) for three months ended September 30, 2026, vs. $0.9 million ($0.06 per share) a year ago
  • Cash and cash equivalents of $21.3 million as of September 30, 2026, up from $17.0 million at March 31, 2026
  • Completed $10 million private placement in August 2026, net proceeds of $9.2 million
  • Cash used in operations for six months ended September 30, 2026 was approximately $5.0 million
  • Company believes cash sufficient through end of calendar 2028
  • Dual-source manufacturing strategy for GTx-104 progressing; NDA resubmission timing depends on whichever manufacturing site reaches readiness first
  • No clinical safety or efficacy deficiencies identified in FDA Complete Response Letter

Financial Impact

Net loss increased by $1.2 million year-over-year; cash increased by $4.3 million from March 31, 2026 due to $9.2M private placement net proceeds

net losscash positionR&D expenses

Risk Factors

  • NDA resubmission timing uncertain, dependent on CMO remediation and FDA scheduling
  • No approved products or revenue; pre-revenue biotech with binary regulatory outcome
  • Potential need for additional capital if NDA resubmission is delayed or requires more resources

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-043308
Document: ef20085030_8k.htm0001140361-26-043308
Document: 0001140361-26-043308-index-headers.html0001140361-26-043308
Document: 0001140361-26-043308-index.html0001140361-26-043308
Document: 0001140361-26-043308.txt0001140361-26-043308
8-K Data (Synthetic)0001140361-26-043308

Track record

15 reports on GRCE

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +10.64% at T+5 after the Apr 23, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.75 Now $1.75 0.00% settles Nov 18
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $1.82 Now $1.75 −3.85% settles Nov 17
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $1.81 to $1.81 Now $1.75 −3.31% · 0.00% +0.36% vs SPY
  4. Sep 10, 20269w ago Insider Cluster Bullish 6/10 Entry $2.26 to $2.22 Now $1.75 −22.57% ▼ −1.77% −2.62% vs SPY
  5. Aug 13, 202613w ago 8-K Neutral 5/10 No price data
  6. Aug 13, 202613w ago Press Release Mixed 5/10 Entry $2.07 to $2.16 Now $1.75 −15.46% ▲ +4.35% +4.55% vs SPY
  7. Aug 4, 202614w ago Press Release Neutral 5/10 Entry $2.14 to $2.12 Now $1.75 −18.22% ▼ −0.93% −0.77% vs SPY
  8. Jul 28, 202615w ago 8-K Neutral 5/10 Entry $2.25 to $2.08 Now $1.75 −22.22% ▼ −7.56% −6.02% vs SPY
  9. Jun 18, 202621w ago 8-K Mixed 5/10 Entry $2.38 to $2.26 Now $1.75 −26.47% ▼ −5.04% −4.73% vs SPY
  10. Jun 18, 202621w ago 8-K Bearish 6/10 No price data
Showing 10 of 15

US Market Status

Market Closed · Opens in 7h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026